Erythropoietin Drugs Market to Reach $14.41 Bn by 2032, Fueled by 5.7% CAGR: Johnson & Johnson, Amgen, Roche, Hospira

PORTLAND, OREGON, UNITED STATES, July 8, 2024 /EINPresswire.com/ -- Rise in prevalence of cancer, HIV, anemia, and kidney diseases, surge in level of awareness about the benefits of EPO therapeutics, and commercialization for erythropoietin biosimilars drive the growth of the global erythropoietin drugs market. However, longer duration of treatment, unaffordability of therapeutics, and adverse amount of side effects hinder the market growth. On the contrary, the commercialization of darbepoetin alfa biosimilar and achieving economies of scale across developed regions are expected to open lucrative opportunities for the market players in the future.

As per the report published by Allied Market Research, the global Erythropoietin Drugs Market was pegged at $9.24 billion in 2020, and is estimated to reach $14.41 billion by 2028, growing at a CAGR of 5.7% from 2021 to 2028.

CXOs further added that erythropoietin-alfa segment is anticipated to grow with the highest revenue throughout the forecast period, owing to increase in sales of Epogen. In addition, kidney disorders segment accounted for a major share in 2020, and is expected to exhibit a prominent growth rate during the forecast period, owing to increase in cases of patients. Moreover, North America dominates the global erythropoietin drugs market, owing to the presence of several approved and commercialized erythropoietin biosimilars. Asia-Pacific and LAMEA offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin drugs as compared to North America and Europe.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/59

Key Takeaways:

The darbepoetin-alfa segment is estimated to register the highest CAGR of 7.0% during the forecast period.

The segment is expected to manifest the highest CAGR of 6.5% during the forecast period.

The market across Asia-Pacific is projected to register the highest CAGR of 7.8% from 2021 to 2028.

Covid-19 scenario:

The outbreak of Covid-19 disrupted the workflow in the healthcare sector as the rapid spread of coronavirus forced several industries to shutdown temporarily.

However, the pandemic had a positive effect on the demand for medical services including erythropoietin.

As erythropoietin is used to treat anemia and can be effective against Covid-19, which boosted its demand. Moreover, it has anti-ischemic, anti-apoptotic, and regenerative effects in several tissues such as kidney, lungs, nervous system, retina, and pancreas. Thus, it can be used to treat critically ill patients.

Connect to our Analyst: https://www.alliedmarketresearch.com/connect-to-analyst/59

Erythropoietin Drugs Market Segments:

By PRODUCTS

Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others

By APPLICATIONS

Hematology
Kidney Disorder
Cancer
Others

Geography:

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

Regional Analysis:

North America dominates the global erythropoietin drugs market, owing to presence of several approved and commercialized erythropoietin biosimilars. However, Asia-Pacific is characterized by presence of generic epoetin products. Asia-Pacific and LAMEA offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin drugs as compared to North America and Europe.

For Procurement Information- https://www.alliedmarketresearch.com/purchase-enquiry/59

Leading Market Players:

Johnson & Johnson
Amgen Inc.,
Roche, Hospira Inc.
Biocon
LG Life Sciences Ltd.
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals
Ranbaxy Laboratories Ltd.,
Celltrion, Inc.

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/59

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X